Research programme: metabolic and lipid disorder therapeutics - Spherix

Drug Profile

Research programme: metabolic and lipid disorder therapeutics - Spherix

Alternative Names: SPX 100; SPX 10624258; SPX 723; SPX 7233801; SPX 8522876; SPX 8818309; SPX 8818440; SPX-106; SPX-106T

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Kentucky Research Foundation
  • Developer Spherix
  • Class Hexoses; Small molecules
  • Mechanism of Action Iron chelating agents; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Abdominal aortic aneurysm; Atherosclerosis; Diabetes mellitus; Dyslipidaemias; Metabolic syndrome; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Abdominal-aortic-aneurysm in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top